A recent study using both lipopolysaccharide (LPS) and anti-GBM antibody-induced glomerular disease models showed that podocyte injury could be limited by blocking FAK activation [22], providing further evidence of the potential general utility of FAK inhibitors for the treatment of glomerular diseases. Here, PTK2 is linked to glomerular disorder.